Comparing of MediWound Ltd. (MDWD) and Histogenics Corporation (NASDAQ:HSGX)

Both MediWound Ltd. (NASDAQ:MDWD) and Histogenics Corporation (NASDAQ:HSGX) are Biotechnology companies, competing one another. We will compare their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediWound Ltd. 2.94M 44.76 13.91M -0.51 0.00
Histogenics Corporation N/A 0.00 13.78M -0.43 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for MediWound Ltd. and Histogenics Corporation.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
MediWound Ltd. -473.13% -403.7% -35.9%
Histogenics Corporation 0.00% 66.4% -73.3%

Volatility and Risk

A -0.01 beta indicates that MediWound Ltd. is 101.00% less volatile compared to Standard and Poor’s 500. Histogenics Corporation’s 0.89 beta is the reason why it is 11.00% less volatile than Standard and Poor’s 500.

Liquidity

MediWound Ltd. has a Current Ratio of 5.5 and a Quick Ratio of 5.2. Competitively, Histogenics Corporation’s Current Ratio is 0.7 and has 0.7 Quick Ratio. MediWound Ltd.’s better ability to pay short and long-term obligations than Histogenics Corporation.

Analyst Ratings

Ratings and Recommendations for MediWound Ltd. and Histogenics Corporation can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MediWound Ltd. 0 0 0 0.00
Histogenics Corporation 0 2 0 2.00

Competitively Histogenics Corporation has a consensus target price of $3.5, with potential upside of 2,594.38%.

Institutional and Insider Ownership

Institutional investors held 36.8% of MediWound Ltd. shares and 17.8% of Histogenics Corporation shares. 41.5% are MediWound Ltd.’s share held by insiders. Competitively, 6.2% are Histogenics Corporation’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MediWound Ltd. -9.88% -10.19% -22.39% -21.8% 9.47% 16.85%
Histogenics Corporation 8.67% -13.07% -25.83% -83.15% -75.9% -77.31%

For the past year MediWound Ltd. has 16.85% stronger performance while Histogenics Corporation has -77.31% weaker performance.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.